# A Study of Efavirenz in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs

> **NCT00002227** · PHASE2 · COMPLETED · sponsor: **Dupont Merck** · enrollment: 60 (—)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Efavirenz
- **DRUG:** Lamivudine
- **DRUG:** Stavudine

## Key facts

- **NCT ID:** NCT00002227
- **Lead sponsor:** Dupont Merck
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 60 (—)
- **Last updated:** 2005-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002227

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002227, "A Study of Efavirenz in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00002227. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*